Am I a candidate for treatment
In March 2024, it became the first obesity medication to receive FDA approval for reducing the risk of cardiovascular events, reinforcing its role beyond weight loss
Novo Nordisk Foundation
This documentation helps your clinical team track whether your appetite suppression and weight loss remain stable after the change, and whether your dose requires any adjustment
Vill K, Muller-Felber W, Landfarth T, Koppl C, Herzig N, Knerr C, Holla H, Steidle G, Harms E, Hohenfellner K, Interdisciplinary Cystinosis Group (2022) Neuromuscular conditions and the impact of cystine-depleting therapy in infantile nephropathic cystinosis: a cross-sectional analysis of 55 patients
Conversely, the coadministration of weekly high-dose vitamin D (cholecalciferol 50,000 IU) with antidepressant therapy was associated with significantly improved fatigue scores at weeks 4, 8, and 12 in a case-control study [130]